The Effects of Caffeine on Physical Performance of Ice Hockey Players

NCT ID: NCT05170139

Last Updated: 2023-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To date, only one study has evaluated the effect of caffeine supplementation on athletic performance in ice hockey players finding a lack of ergogenic effect. This lack of effect is surprising as caffeine has been suggested to be an effective and safe nutritional supplement to improve physical performance in both trained and untrained individuals. Therefore, the aim of the present study is to evaluate the effect of acute caffeine ingestion (3mg/kg body mass). Thirteen elite adult ice-hockey male players will perform specific ice hockey performance tests in two separate days. On both occasions players will ingest 330 ml of water with lemon powertabs isostar® (86 kcal / 19g of carbohydrates) tablets, which will include in one of these days 3 mg/kg body mass of anhydrous caffeine. Players will perform a 35-m sprint, an agility test (Weave agility - slalom with puck), and a reaction test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Caffeine Athletic Performance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Participants will be given a bottle with either caffeine and carbohydrates or just carbohydrates. All participants will complete ice-hockey specific athletic tests in both conditions.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Participants will be given a bottle with either caffeine and carbohydrates or just carbohydrates.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Caffeine

Dietary Supplement: Caffeine supplementation Participants will ingest caffeine in liquid form (3mg/kg) with carbohydrates.

Group Type EXPERIMENTAL

Caffeine

Intervention Type DIETARY_SUPPLEMENT

Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates

Control condition

Participants will ingest a drink of carbohydrates without caffeine

Group Type PLACEBO_COMPARATOR

Placebo drink

Intervention Type DIETARY_SUPPLEMENT

Participants will ingest the exact same drink without caffeine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Caffeine

Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates

Intervention Type DIETARY_SUPPLEMENT

Placebo drink

Participants will ingest the exact same drink without caffeine

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years,
* Male
* Play in the Spanish ice hockey first division.

Exclusion Criteria

* Participants taking drugs containing ephedrine or antibiotics.
* Having suffered a musculoskeletal injury in the 3 months prior to the tests.
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad de Zaragoza

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alejandro Gómez Bruton

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universidad de Zaragoza

Zaragoza, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Caffeinehockey

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.